# Avantor, Inc.: Form 10-Q for the period ended Sep 30, 2022

- Company: [Avantor, Inc.](/companies/avtr.md) (CIK 1722482)
- Form: 10-Q
- Filed: 2022-10-28
- Accepted by EDGAR: Oct 28, 2022, 09:06 ET
- Period: 2022-09-30
- Accession: 0001722482-22-000186
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1722482/000172248222000186/avtr-20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1722482/000172248222000186/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-01 to 2022-09-30 | $1.86bn | us-gaap:Revenues |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $5.72bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2022-07-01 to 2022-09-30 | $1.21bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2022-01-01 to 2022-09-30 | $3.73bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-07-01 to 2022-09-30 | $650.7m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-01-01 to 2022-09-30 | $1.99bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2022-07-01 to 2022-09-30 | $374.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2022-01-01 to 2022-09-30 | $1.11bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-07-01 to 2022-09-30 | $275.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-01-01 to 2022-09-30 | $878.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-07-01 to 2022-09-30 | $67.3m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2022-01-01 to 2022-09-30 | $196.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-07-01 to 2022-09-30 | $41.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | $131.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | $167.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | $544.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | $0.25 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | $0.80 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | $0.25 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | $0.81 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 679,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 680,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | $638.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-01-01 to 2022-09-30 | $99.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-09-30 | $265.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $2.56bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $13.11bn | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $1.55bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $8.52bn | us-gaap:Liabilities |
| Long-term debt | at 2022-09-30 | $5.91bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2022-09-30 | $280.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-09-30 | $4.59bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 29,902 characters.

*In addition to historical financial information, this discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our results may differ materially from those contained in or implied by any forward-looking statements. You should carefully read “Cautionary factors regarding forward-looking statements” for additional information.*

### Basis of presentation

This discussion should be read in conjunction with the accompanying condensed consolidated financial statements and notes. Pursuant to SEC rules for reports covering interim periods, we have prepared this discussion and analysis to enable you to assess material changes in our financial condition and results of operations since December 31, 2021, the date of our Annual Report. Therefore, we encourage you to read this discussion and analysis in conjunction with the Annual Report.

### Overview

We are a leading global provider of mission critical products and services to customers in the biopharmaceutical, healthcare, education & government and advanced technologies & applied materials industries. We have global operations and an extensive product portfolio. We strive to enable customer success through innovation, cGMP manufacturing and comprehensive service offerings. The depth and breadth of our portfolio provides our customers a comprehensive range of products and services and allows us to create customized and integrated solutions for our customers.

During the three months ended September 30, 2022, we recorded net sales of $1,856.5 million, net income of $167.0 million and Adjusted EBITDA of $384.0 million. Net sales increased by 1.2%, which included 4.5% organic growth compared to the same period in 2021. See “Reconciliations of non-GAAP measures” for a reconciliation of net income to Adjusted EBITDA and “Results of operations” for a reconciliation of net sales growth to organic net sales growth.

### Factors and current trends affecting our business and results of operations

The following updates the factors and current trends disclosed in the Annual Report. These updates could affect our performance and financial condition in future periods.

### Our results are impacted by acquisitions

We completed the acquisitions of Masterflex, Ritter GmbH, and RIM Bio in 2021. Masterflex is a leading global manufacturer of peristaltic pumps and aseptic single-use fluid transfer technologies. Ritter GmbH is focused on supplying high-quality liquid handling consumables used in a variety of molecular screening and diagnostic applications and as part of drug discovery and clinical trial testing in pharma and biotech applications. RIM Bio provides a complete range of single-use 2D bags, 3D bags, tank liners, bag assemblies and multi-bag manifolds used in the manufacturing of biologics including monoclonal antibodies (mAbs), vaccines, cell and gene therapies, and recombinant proteins.

### Our results continue to be impacted by the ongoing global coronavirus outbreak

The results for each of our three regions continue to be impacted by the COVID-19 pandemic for the three and nine months ended September 30, 2022, as described further in the “Results of operations” section below. For a discussion of the impact of the COVID-19 pandemic and associated economic disruptions, and the actual operational and financial impacts that we experienced through December 31, 2021, see “Part II—Item 7—Management's discussion and analysis of financial condition and results of operations” in the Annual Report. For additional discussion of the potential impact of the COVID-19 pandemic and associated economic disruptions on our results, see “The COVID-19 pandemic has adversely impacted, and continues to pose risks to, our business, operating results, cash flows and/or financial condition, the nature and extent of which could be material.” included in “Part I—Item 1A—Risk factors” in the Annual Report.

### We have been impacted by supply chain constraints and inflationary pressures

We have experienced challenges in sourcing certain products and raw materials as a result of global supply chain disruptions and have experienced inflationary pressures across all of our cost categories. While we have implemented pricing and productivity measures to combat these pressures, they may continue to adversely impact our results.

### Fluctuations in foreign currency rates impact our results

Our consolidated results of operations are comprised of many different functional currencies that translate into our U.S. Dollar reporting currency. The movement of the U.S. Dollar against those functional currencies, particularly the Euro, has caused significant variability in our results and may continue to do so in the future.

### Key indicators of performance and financial condition

To evaluate our performance, we monitor a number of key indicators including certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly-titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business.

The key indicators that we monitor are as follows:

- ***Net sales, gross margin, operating income*** and ***net income or loss***. These measures are discussed in the section entitled “Results of operations;”
- ***Organic net sales growth,*** which is a non-GAAP measure discussed in the section entitled “Results of operations.” Organic net sales growth eliminates from our reported net sales the impacts of earnings from any acquired or disposed businesses and changes in foreign currency exchange rates. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measurement is used by our management for the same reason. Reconciliations to the change in reported net sales, the most directly comparable GAAP financial measure, are included in the section entitled “Results of operations;”
- ***Adjusted EBITDA and Adjusted EBITDA margin***, which are non-GAAP measures discussed in the section entitled “Results of operations.” Adjusted EBITDA is used by investors to measure and evaluate our operating performance exclusive of interest expense, income tax expense, depreciation, amortization and certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measurements are useful to investors as a way to analyze the underlying trends in our business consistently across the periods presented. This measurement is used by our management for the same reason. A reconciliation of net income or loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA is included in the section entitled “Reconciliations of non-GAAP measures;”
- ***Cash flows from operating activities***, which we discuss in the section entitled “Liquidity and capital resources—Historical cash flows;”
- ***Free cash flow***, which is a non-GAAP measure, is equal to our cash flow from operating activities, plus acquisition-related costs paid in the period, less capital expenditures. We believe that this measurement is useful to investors as it provides a view on the Company’s ability to generate cash for use in financing or investing activities. This measurement is used by management for the same reason. A reconciliation of cash flows from operating activities, the most directly comparable GAAP financial measure, to free cash flows, is included in the section entitled “Liquidity and capital resources—Historical cash flows.”

### Results of operations

We present results of operations in the same way that we manage our business, evaluate our performance and allocate our resources. We also provide discussion of net sales and Adjusted EBITDA by geographic segment based on customer location: Americas, Europe and AMEA. Corporate costs are managed on a standalone basis and not allocated to segments.

### Executive summary

*(dollars in millions)*

| 2022 | Three months ended September 30, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Net sales | $1,856.5 | $1,834.3 | $22.2 |
| Gross margin | 35.0% | 33.6% | 140 bps |
| Operating income | $275.8 | $237.2 | $38.6 |
| Net income | 167.0 | 156.8 | 10.2 |
| Adjusted EBITDA | 384.0 | 359.2 | 24.8 |
| Adjusted EBITDA margin | 20.7% | 19.6% | 110 bps |

Third quarter net sales growth was driven by our biopharma and advanced technologies & applied materials end markets, as well as the impact of the Masterflex acquisition that we completed in the prior year, partially offset by unfavorable foreign currency impact and COVID-19 related headwinds. Commercial excellence, growth of our proprietary materials and consumables product group and sales of higher-margin products offered by recently acquired companies contributed to expansion in both gross margin and Adjusted EBITDA margin.

### Net Sales

#### Three months ended

*(in millions)*

| 2022 | Three months ended September 30, Net sales growth 2021 | Foreign currency impact | Reconciliation of net sales growth to organic net sales growth M&A impact | Organic net sales growth |  |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Americas | $1,123.2 | $1,045.0 | $78.2 | $(4.0) | $30.5 | $51.7 |
| Europe | 595.1 | 674.7 | (79.6) | (93.4) | 7.1 | 6.7 |
| AMEA | 138.2 | 114.6 | 23.6 | (9.1) | 8.9 | 23.8 |
| Total | $1,856.5 | $1,834.3 | $22.2 | $(106.5) | $46.5 | $82.2 |

Net sales increased $22.2 million or 1.2%, which included $106.5 million or 5.8% of unfavorable foreign currency impact and $46.5 million or 2.5% of M&A impact. Organic growth was $82.2 million or 4.5% (7.8% when excluding the impact of sales of COVID-19-related products in both periods, referred to herein as COVID-19 related headwinds or tailwinds) and was primarily due to growth in our proprietary products and services.

In the Americas, net sales increased $78.2 million or 7.5%, which included $4.0 million or 0.3% of unfavorable foreign currency impact and $30.5 million or 2.9% of M&A impact. Organic growth in net sales was $51.7 million or 4.9% (8.8% excluding COVID-19 headwinds). Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is as follows:

- *Biopharma (55%) —* Sales grew mid single-digits, primarily due to strong growth in sales of proprietary materials in biopharma production driven by our chemicals and serum product offerings, partially offset by reduced sales of COVID-19 related products.
- *Healthcare (10%) —* Sales were flat as strong growth in our medical grade silicone business was offset by declines in COVID-19 related offerings for diagnostic testing.
- *Education and government (15%) —* Sales increased low single-digits primarily due to increases in lab chemicals and equipment & instrumentation to government customers, partially offset by lower sales of COVID-19 related offerings to university research customers.
- *Advanced technologies & applied materials (20%) —* Sales increased double-digits driven by strong sales to our semiconductor and electronic device customers.

In Europe, net sales decreased $79.6 million or 11.8%, which included $93.4 million or 13.9% of unfavorable foreign currency impact and $7.1 million or 1.1% of M&A impact. Organic net sales increased $6.7 million or 1.0% (4.8% excluding COVID-19 headwinds). Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is as follows:

- *Biopharma (50%) —* Sales grew low single-digits driven by double-digit growth in our production chemicals and single-use offerings, partially offset by lower sales of COVID-19 related offerings for vaccines, PPE and diagnostic testing.
- *Healthcare* (10%) — Sales increased double-digits primarily due to strong growth in our medical grade silicone offering.
- *Education & government (10%) —* Sales declined high single-digits driven by decreased sales of equipment & instrumentation in the education end market and by COVID-19 related headwinds in the government end market.
- *Advanced technologies & applied materials (30%) —* Sales decreased low single-digits due to softer industrial demand and COVID-19 headwinds.

In AMEA, net sales increased $23.6 million or 20.6%, which included $9.1 million or 8.0% of unfavorable foreign currency impact and $8.9 million or 7.8% of M&A impact. The organic increase in net sales was $23.8 million or 20.8% (15.1% excluding COVID-19 tailwinds). Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is as follows:

- *Biopharma (50%) —* Sales increased double-digits due to growth in sales of proprietary materials in biopharma production driven by our chemicals and single-use product offerings.
- *Advanced technologies & applied materials (40%) —* Sales grew double-digits primarily driven by growth of our proprietary offerings into the semiconductor industry as well as strong industrial demand in the region.

#### Nine months ended

*(in millions)*

| 2022 | Nine months ended September 30, Net sales growth 2021 | Foreign currency impact | Reconciliation of net sales growth to organic net sales growth M&A Impact | Organic net sales growth |  |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Americas | $3,423.2 | $3,149.9 | $273.3 | $(8.8) | $123.0 | $159.1 |
| Europe | 1,899.3 | 1,991.1 | (91.8) | (204.1) | 90.1 | 22.2 |
| AMEA | 394.9 | 337.5 | 57.4 | (17.6) | 41.1 | 33.9 |
| Total | $5,717.4 | $5,478.5 | $238.9 | $(230.5) | $254.2 | $215.2 |

Net sales increased $238.9 million or 4.4%, which included $230.5 million or 4.1% of unfavorable foreign currency impact and $254.2 million or 4.6% of M&A impact. Organic growth in net sales was $215.2 million or 3.9% (7.1% excluding COVID-19 headwinds).

In the Americas, net sales increased $273.3 million or 8.7%, which included $8.8 million or 0.3% of unfavorable foreign currency impact and $123.0 million or 3.9% of M&A impact. Organic growth in net sales was $159.1 million or 5.1% (8.2% excluding COVID-19 headwinds) for reasons similar to the three month period.

In Europe, net sales decreased $91.8 million or 4.6%, which included $204.1 million or 10.2% of unfavorable foreign currency impact and $90.1 million or 4.5% of M&A impact. Organic growth in net sales was $22.2 million or 1.1% (5.2% excluding COVID-19 headwinds) for reasons similar to the three month period as well as modest growth in our advanced technologies & applied materials business.

In AMEA, net sales increased $57.4 million or 17.0%, which included $17.6 million or 5.2% of unfavorable foreign currency impact and $41.1 million or 12.2% of M&A impact. Organic growth in net sales was $33.9 million or 10.0% (7.6% excluding COVID-19 tailwinds) for reasons similar to the three month period partially offset by the impact of supply constraints and COVID-19 related lockdowns in China in the second quarter of 2022.

### Gross margin

| 2022 | Three months ended September 30, 2021 | 2022 | Change 2021 | Nine months ended September 30, |  | Change |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Gross margin | 35.0% | 33.6% | 140 bps | 34.8% | 33.9% | 90 bps |

#### Three and nine months ended

Gross margin for the three and nine months ended September 30, 2022 increased 140 basis points and 90 basis points, respectively, resulting primarily from commercial excellence and favorable product mix in our proprietary materials business, as well as a favorable impact from sales of higher gross margin products from acquired companies.

### Operating income

*(in millions)*

| 2022 | Three months ended September 30, 2021 | 2022 | Change 2021 | Nine months ended September 30, |  | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Gross profit | $650.7 | $615.9 | $34.8 | $1,988.3 | $1,855.2 | $133.1 |
| Operating expenses | 374.9 | 378.7 | (3.8) | 1,109.9 | 1,097.0 | 12.9 |
| Operating income | $275.8 | $237.2 | $38.6 | $878.4 | $758.2 | $120.2 |

#### Three and nine months ended

Operating income increased primarily from higher gross profit, as previously discussed. For the three months ended September 30, 2022, we have lower operating expenses driven by productivity and foreign currency impacts. On a year to date basis, the increase in operating expenses is driven by an additional $39.5 million in non-cash amortization expense related to intangible assets generated in our 2021 acquisitions, as well as investments in our workforce made over the course of 2021 and into 2022.

### Net income

*(in millions)*

| 2022 | Three months ended September 30, 2021 | 2022 | Change 2021 | Nine months ended September 30, |  | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $275.8 | $237.2 | $38.6 | $878.4 | $758.2 | $120.2 |
| Interest expense | (67.3) | (54.1) | (13.2) | (196.0) | (156.6) | (39.4) |
| Loss on extinguishment of debt | (2.9) | — | (2.9) | (10.8) | (8.4) | (2.4) |
| Other income, net | 2.7 | 3.4 | (0.7) | 4.8 | 19.8 | (15.0) |
| Income tax expense | (41.3) | (29.7) | (11.6) | (131.6) | (134.4) | 2.8 |
| Net income | $167.0 | $156.8 | $10.2 | $544.8 | $478.6 | $66.2 |

#### Three months ended

Net income increased due to higher operating income, as previously discussed. This growth was partially offset by higher interest expense driven by incremental debt issued in the fourth quarter of 2021 to finance the Masterflex acquisition, loss on extinguishment of our debt resulting from optional prepayments on our term loans, and higher income tax expense driven by higher income before income taxes and lower tax deductions resulting primarily from fewer stock option exercises in 2022 compared to 2021.

#### Nine months ended

Net income increased primarily due to higher operating income, as previously discussed. This was partially offset by higher interest expense as a result of incremental debt issued to finance the acquisitions completed in 2021, and lower other income resulting from the absence of a one-time disgorgement penalty payment that we received in 2021.

### Adjusted EBITDA and Adjusted EBITDA margin

For a reconciliation of Adjusted EBITDA to Net income, the most directly comparable measure under GAAP, see “Reconciliations of non-GAAP financial measures.”

*(dollars in millions)*

| 2022 Adjusted EBITDA: | Three months ended September 30, 2021 | 2022 | Change 2021 | Nine months ended September 30, |  | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Americas | $262.3 | $236.3 | $26.0 | $846.3 | $740.0 | $106.3 |
| Europe | 130.3 | 135.5 | (5.2) | 393.0 | 390.4 | 2.6 |
| AMEA | 35.7 | 29.5 | 6.2 | 101.1 | 80.5 | 20.6 |
| Corporate | (44.3) | (42.1) | (2.2) | (129.2) | (122.0) | (7.2) |
| Total | $384.0 | $359.2 | $24.8 | $1,211.2 | $1,088.9 | $122.3 |
| Adjusted EBITDA margin | 20.7% | 19.6% | 110 bps | 21.2% | 19.9% | 130 bps |

#### Three months ended

Adjusted EBITDA increased $24.8 million or 6.9%, which included an unfavorable foreign currency translation impact of $21.2 million or 5.9% and $19.6 million or 5.5% from M&A. The remaining growth was $26.4 million or 7.3%.

In the Americas, Adjusted EBITDA grew $26.0 million or 11.0%, or 5.1% when adjusted for unfavorable foreign currency translation impact and M&A. Higher gross profit driven by commercial excellence and favorable mix related to sales of our higher-margin proprietary products was partially offset by inflationary factors and investments in our workforce made over the course of 2021 and into 2022.

In Europe, Adjusted EBITDA declined $5.2 million or 3.8%, but increased 9.0% when adjusted for unfavorable foreign currency translation impact and M&A. The increase was driven by higher gross profit resulting from favorable product mix and commercial excellence. This increase was partially offset by inflationary factors and investments in our workforce made over the course of 2021 and into 2022.

In AMEA, Adjusted EBITDA grew $6.2 million or 21.0%, or 14.2% when adjusted for unfavorable foreign currency translation impact and M&A. Increases driven by higher gross profit were partially offset by inflationary factors and losses on foreign currency revaluations.

In Corporate, Adjusted EBITDA declined $2.2 million or 5.3% reflecting investments in our workforce made over the course of 2021 and into 2022 and increased equity-classified stock-based compensation expense.

#### Nine months ended

Adjusted EBITDA increased $122.3 million or 11.2%, which included an unfavorable foreign currency translation impact of $44.0 million or 4.0% and $95.1 million or 8.7% from M&A. The remaining growth was $71.2 million or 6.5%.

In the Americas, Adjusted EBITDA grew $106.3 million or 14.4%, or 7.0% when adjusted for unfavorable foreign currency translation impact and M&A. Higher gross profit from commercial excellence and favorable product mix related to sales of our higher-margin proprietary products was partially offset by inflationary factors, including freight, and investments in our workforce made over the course of 2021 and into 2022.

In Europe, Adjusted EBITDA grew $2.6 million or 0.7%, or 4.7% when adjusted for unfavorable foreign currency translation impact and M&A, due to higher gross profit from favorable product mix and commercial excellence. This was partially offset by inflationary factors, including freight, and investments in our workforce made over the course of 2021 and into 2022.

In AMEA, Adjusted EBITDA grew $20.6 million or 25.6%, or 9.3% when adjusted for unfavorable foreign currency translation impact and M&A. Increases driven by higher gross profit were offset by inflationary factors, including freight.

In Corporate, Adjusted EBITDA declined $7.2 million or 5.9% reflecting investments in our workforce made over the course of 2021 and into 2022 and increased equity-classified stock-based compensation expense.

### Reconciliations of non-GAAP financial measures

The following table presents the reconciliation of net income to Adjusted EBITDA:

*(in millions)*

| 2022 | Three months ended September 30, 2021 | 2022 | Nine months ended September 30, 2021 |  |
| --- | ---: | ---: | ---: | ---: |
| Net income | $167.0 | $156.8 | $544.8 | $478.6 |
| Interest expense | 67.3 | 54.1 | 196.0 | 156.6 |
| Income tax expense | 41.3 | 29.7 | 131.6 | 134.4 |
| Depreciation and amortization | 100.6 | 100.0 | 304.8 | 275.1 |
| Loss on extinguishment of debt | 2.9 | — | 10.8 | 8.4 |
| Net foreign currency (gain) loss from financing activities | (1.2) | (0.8) | (0.2) | 1.2 |
| Other stock-based compensation (benefit) expense | (1.6) | 1.6 | (3.3) | 2.9 |
| Acquisition-related expenses1 | — | 3.2 | — | 27.8 |
| Integration-related expenses2 | 6.4 | 7.9 | 13.6 | 8.4 |
| Purchase accounting adjustments3 | — | 6.3 | 9.4 | 6.3 |
| Restructuring and severance charges4 | 1.3 | 0.4 | 3.7 | 2.2 |
| Receipt of disgorgement penalty5 | — | — | — | (13.0) |
| Adjusted EBITDA | $384.0 | $359.2 | $1,211.2 | $1,088.9 |

1\. Represents legal, accounting, investment banking and consulting fees incurred related to the acquisition of acquired companies.

2\. Represents non-recurring direct costs incurred with third parties to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.

3\. Represents the non-cash reduction of contingent consideration related to the Ritter acquisition and the amortization of the purchase accounting adjustments to record inventory acquired from Masterflex and Ritter at fair value.

4\. Reflects the incremental expenses incurred in the period related to initiatives to increase profitability and productivity. Typical costs included in this caption are employee severance, site-related exit costs, and contract termination costs.

5\. As described in note 12 to our unaudited interim financial statements.

### Liquidity and capital resources

We fund short-term cash requirements primarily from operating cash flows. Most of our long-term financing is from indebtedness. For the three and nine months ended September 30, 2022, we generated $258.3 million and $638.0 million of cash from operating activities, ended the quarter with $265.6 million of cash and cash equivalents and our availability under our credit facilities was $556.1 million. We have no debt repayments due in the next twelve months other than required term loan payments of $31.7 million and receivables facility borrowing of $245.0 million.

### Liquidity

The following table presents our primary sources of liquidity:

*(in millions)*

| September 30, 2022 Receivables facility Revolving credit facility Total Unused availability under credit facilities: |  |
| --- | ---: |
| Capacity $300.0 $515.0 | $815.0 |
| Undrawn letters of credit outstanding (13.9) — | (13.9) |
| Outstanding borrowings (245.0) — | (245.0) |
| Unused availability $41.1 $515.0 | $556.1 |
| Cash and cash equivalents | 265.6 |
| Total liquidity | $821.7 |

We fund short-term cash requirements primarily from operating cash flows. Some of our credit line availability depends upon maintaining a sufficient borrowing base of eligible accounts receivable. We believe that we have sufficient capital resources to meet our liquidity needs.

Our debt agreements include representations and covenants that we consider usual and customary, and our receivables facility and senior secured credit facilities include a financial covenant that becomes applicable for periods in which we have drawn more than 35% of our revolving credit facility under the senior secured credit facilities. In this circumstance, we are not permitted to have combined borrowings on our senior secured credit facilities and secured notes in excess of a pro forma net leverage ratio, as defined in our credit agreements. As we had not drawn more than 35% of our revolving credit facility in this period, this covenant was not applicable at September 30, 2022.

At September 30, 2022, $229.5 million or 86.4% of our $265.6 million in cash and cash equivalents was held by our non-U.S. subsidiaries and may be subject to certain taxes upon repatriation, primarily where foreign withholding taxes apply.

### Historical cash flows

The following table presents a summary of cash provided by (used in) various activities:

*(in millions)*

| 2022 Operating activities: | Nine months ended September 30, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Net income | $544.8 | $478.6 | 66.2 |
| Non-cash items1 | 350.5 | 347.1 | 3.4 |
| Working capital changes2 | (155.1) | (175.1) | 20.0 |
| All other | (102.2) | 2.0 | (104.2) |
| Total | $638.0 | $652.6 | $(14.6) |
| Investing activities | $(76.5) | $(1,238.2) | $1,161.7 |
| Cash paid for acquisitions, net of cash acquired | (20.2) | (1,168.9) | 1,148.7 |
| Capital expenditures | (99.8) | (71.1) | (28.7) |
| Cash proceeds from settlement of cross currency swap | 42.5 | — | 42.5 |
| Financing activities | (567.1) | 1,758.2 | (2,325.3) |

1\. Consists of typical non-cash charges including depreciation and amortization, stock based compensation expense, deferred income tax expense and others.

2\. Includes changes to our accounts receivable, inventory, contract assets and accounts payable.

Cash flows from operating activities provided $14.6 million less cash in 2022 primarily due to higher payments for interest and tax, higher incentive compensation payments for fiscal year 2021 company performance, and higher payments to customers under our rebate programs driven by the strong 2021 volumes. These items were partially offset by higher operating income.

Investing activities used $1,161.7 million less cash in 2022, reflecting the cash paid for acquisitions in the previous year as well as cash we received from the settlement of a cross currency swap in the third quarter of 2022. These items were offset by increased capital spending across the Company compared to the prior year.

Financing activities used $2,325.3 million more cash in 2022 compared to the prior year. In 2021, financing activities provided $1,758.2 million of cash primarily due to issuances of new debt and secondary equity offerings to finance our acquisitions. In 2022, we used $567.1 million of cash primarily to pay down our term loans.

### Free cash flow

*(in millions)*

| 2022 | Nine months ended September 30, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Net cash provided by operating activities | $638.0 | $652.6 | $(14.6) |
| Acquisition-related expenses paid | — | 24.6 | $(24.6) |
| Capital expenditures | (99.8) | (71.1) | (28.7) |
| Free cash flow | $538.2 | $606.1 | $(67.9) |

Free cash flow was $67.9 million lower in 2022 due to the changes in cash flows from operating activities noted above and an increase in capital spending in 2022, principally reflecting growth-related expansions in our global supply chain.

### Indebtedness

For information about our indebtedness, refer to the section entitled “Liquidity” and note 9 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements.”

### New accounting standards

There were no new accounting standards that we expect to have a material impact on our financial position or results of operations upon adoption.

## Controls and procedures

As filed, 1,014 characters.

### Management’s evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2022, the design and operation of our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.

### Changes in internal control over financial reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) during the fiscal quarter ended September 30, 2022 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 316 characters.

For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report. There have been no material changes to the risk factors disclosed in Part I—Item 1A of the Annual Report.

Filed Oct 28, 2022.
Source: SEC EDGAR, the filing index for accession 0001722482-22-000186. Last ingested by Listed: Nov 13, 2026, 16:45 ET. No prices; not investment advice.
